Results 161 to 170 of about 1,491,651 (251)

Case Report: Upadacitinib and apremilast combination therapy for guselkumab-induced paradoxical eczema in psoriasis. [PDF]

Front Immunol
Yang L, Zhou J, Ruan Z, Shi K.
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

The Inverted Pyramid Approach: Early Combination Therapy With Voclosporin and Obinutuzumab in Active Lupus Nephritis. [PDF]

Cureus
Timlin H, Koirala A, Geetha D, Azar A, Mener A.   +4 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Targeting Metabolic Vulnerabilities in Glioblastoma: a Framework for Multi-node Combination Therapy. [PDF]

Curr Oncol Rep
Gokani V, Kotta A, Repaka V, Rauniyar S, Noch EK.   +4 more
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

The impact of vancomycin and piperacillin-tazobactam combination therapy on the incidence of acute kidney injury: a retrospective review. [PDF]

Proc (Bayl Univ Med Cent)
Cain D, Demla S, Kway K, Graham A, Hawkins R, Naushab M, Shaffer N, Taqvi S, Myer R, Toups N, Yarger T, Baskett B, Quach E, McKeefer H, Nguyen A, Youree B, Ramarathnam V, Moise D, Shori S, Gautam S.   +19 more
europepmc   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Real-World Safety and Efficacy of a Pitavastatin-Ezetimibe Combination Therapy in Taiwanese Patients after PCI. [PDF]

Acta Cardiol Sin
Lu YW, Fang CC, Cheng YT.
europepmc   +1 more source